Alexion Pharma (ALXN) Announces Restructuring, Including Workforce Reduction of 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Alexion Pharma (ALXN) Announces Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment
September 14, 2017 5:37 AM EDTAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results show sustained treatment benefits across a range of MG-specific assessment scales through an additional 52 weeks for patients who continued to receive Soliris, and also demonstrate rapid, significant and sustained improvements through 52 weeks for patients who had crossed over from placebo in REGAIN to Soliris treatment in... More
Alexion Pharmaceuticals (ALXN) PT Raised to $158 at Deutsche Bank Following Restructuring News
September 13, 2017 7:54 AM EDTDeutsche Bank raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158.00 (from $153.00) while maintaining a Buy rating following the company's restructuring announcement.
Analyst... More
Alexion Pharmaceuticals (ALXN) PT Raised to $182 at Leerink Partners
September 13, 2017 6:46 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $182.00 (from $170.00) while maintaining a Outperform rating following yesterday's reconstructing news.
Analyst Geoffrey Porges sees more good news to come, gMG Plus leverage offers upside.
... MoreAlexion Pharmaceuticals (ALXN) PT Raised to $180 at SunTrust Robinson Humphrey
September 12, 2017 1:38 PM EDTSunTrust Robinson Humphrey analyst Yatin Suneja raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $180.00 (from $170.00) while maintaining a Buy rating after the company announced a restructuring to re-align the company with its previously announced strategic plan.
Suneja commented, "While today's... More
Alexion Pharmaceuticals (ALXN) PT Raised to $173 at BMO Capital
September 12, 2017 11:59 AM EDTBMO Capital analyst M. Ian Somaiya raised his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $173.00 (from $168.00) while maintaining a Outperform rating as the company's plan to cut 20% of its workforce leading to $250mn annual savings was foreshadowed by prior guidance of non-GAAP operating... More
Alexion Pharma (ALXN) to Host Call to Discuss Restructuring Tomorrow
September 11, 2017 4:24 PM EDTAlexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.m. ET. Following the release, Alexion management will conduct a conference call and audio webcast on... More
